Edaravone: A new drug approved for ALS

Research output: Contribution to journalShort surveypeer-review

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone. Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

Original languageEnglish (US)
Pages (from-to)725
Number of pages1
JournalCell
Volume171
Issue number4
DOIs
StatePublished - Nov 2 2017

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Edaravone: A new drug approved for ALS'. Together they form a unique fingerprint.

Cite this